ZA961481B - Isolated nonapeptides presented by hla molecules and uses thereof - Google Patents

Isolated nonapeptides presented by hla molecules and uses thereof

Info

Publication number
ZA961481B
ZA961481B ZA961481A ZA961481A ZA961481B ZA 961481 B ZA961481 B ZA 961481B ZA 961481 A ZA961481 A ZA 961481A ZA 961481 A ZA961481 A ZA 961481A ZA 961481 B ZA961481 B ZA 961481B
Authority
ZA
South Africa
Prior art keywords
presented
hla molecules
nonapeptides
isolated
isolated nonapeptides
Prior art date
Application number
ZA961481A
Other languages
English (en)
Inventor
Theirry Boon-Falleur
Pierre Van Der Bruggen
Etienne De Plaen
Christoph Lurquin
Beatrice Gaugler
Benoit Van Der Eynde
Catia Traversari
Pedro Romero
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA961481B publication Critical patent/ZA961481B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA961481A 1995-02-23 1996-02-23 Isolated nonapeptides presented by hla molecules and uses thereof ZA961481B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/393,273 US6222012B1 (en) 1992-08-31 1995-02-23 Isolated nonapeptides presented by HLA molecules, and uses thereof

Publications (1)

Publication Number Publication Date
ZA961481B true ZA961481B (en) 1996-07-23

Family

ID=23554022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961481A ZA961481B (en) 1995-02-23 1996-02-23 Isolated nonapeptides presented by hla molecules and uses thereof

Country Status (9)

Country Link
US (1) US6222012B1 (fr)
EP (1) EP0811013A4 (fr)
JP (1) JP3096739B2 (fr)
CN (1) CN1175954A (fr)
AU (1) AU693664B2 (fr)
CA (1) CA2213337A1 (fr)
NZ (1) NZ303414A (fr)
WO (1) WO1996026214A1 (fr)
ZA (1) ZA961481B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
AU2001229681A1 (en) * 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
DK2267021T3 (en) 2002-09-12 2015-03-30 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
WO2006113540A2 (fr) * 2005-04-14 2006-10-26 Duke University Utilisation d'un agent qui restaure l'irrigation et l'oxygenation des tissus
CN102356155B (zh) 2009-03-18 2016-02-24 肿瘤疗法科学股份有限公司 Neil3肽及包含它的疫苗
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2016094309A1 (fr) 2014-12-10 2016-06-16 Myosotis Inhibition de la signalisation de tnf en immunothérapie du cancer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
WO2018127917A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion pd1-41bbl et ses méthodes d'utilisation
AU2018205890B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A sirpalpha-41BBL fusion protein and methods of use thereof
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CN111836635A (zh) 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白
WO2020012486A1 (fr) 2018-07-11 2020-01-16 Kahr Medical Ltd. Protéine de fusion du variant de sirpalpha-4-1bbl et procédés d'utilisation associés
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020041662A1 (fr) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunothérapie avec expression d'enzyme métabolique
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
AU2020311636A1 (en) 2019-07-11 2022-03-03 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (fr) 2019-12-31 2021-07-08 Kahr Medical Ltd. Procédés de culture de lymphocytes t avec un polypeptide de fusion 4-1bbl et leurs utilisations
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190127A1 (fr) * 1984-08-10 1986-08-13 MERCK PATENT GmbH Agents polypeptides immunotherapeutiques
AU8305491A (en) 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.

Also Published As

Publication number Publication date
AU693664B2 (en) 1998-07-02
JPH11500137A (ja) 1999-01-06
EP0811013A4 (fr) 1998-12-09
NZ303414A (en) 1998-12-23
AU4971596A (en) 1996-09-11
CN1175954A (zh) 1998-03-11
CA2213337A1 (fr) 1996-08-29
JP3096739B2 (ja) 2000-10-10
EP0811013A1 (fr) 1997-12-10
WO1996026214A1 (fr) 1996-08-29
US6222012B1 (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ZA961481B (en) Isolated nonapeptides presented by hla molecules and uses thereof
IL122428A0 (en) Minizymes and minribozymes and uses thereof
GB9525719D0 (en) Speech system
GB2298852B (en) Suitcase
GB2306554B (en) Clipboard
GB9610897D0 (en) Supercharger
GB9503149D0 (en) Macerator
GB2297502B (en) Harvester-knife cylinder and blower-assist
GB9521660D0 (en) Polycyclic dyes
GB2295580B (en) Notepads
EP0736269A3 (fr) Valise
GB9523580D0 (en) Gas analysis
CA77029S (en) Sign
GB9501868D0 (en) Assays and uses thereof
GB9519112D0 (en) Luggage
GB9514002D0 (en) Flagstaff
AU125364S (en) An ornament
AU130383S (en) An ornament
AU125362S (en) An ornament
AU130385S (en) An ornament
AU125368S (en) An ornament
AU125363S (en) An ornament
AU125361S (en) An ornament
AU130384S (en) An ornament
AU125367S (en) An ornament